Drug Trial Radar · NCT06440967
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
982
Actual
Start
Jul 31, 2024
Primary completion
Jun 25, 2026
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it. The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo. Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having hormone therapy for breast cancer from stage 0 (cancer cells that have not spread to nearby tissue) up to stage 3+ (the cancer has spread from the breast to the lymph nodes near the breast or the chest wall). The women will be assigned 1 of 2 study treatments (fezolinetant or placebo) by chance alone. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study treatments (fezolinetant or placebo). Women who take part in the study will take 1 tablet every day for 52 weeks (1 year). Each woman will be given an electronic handheld device with an app to track their hot flashes on a daily basis. Some women may be able to use the app on their own smartphone. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic about every 4 weeks for a health check. The last clinic visit will be 3 weeks after the women take their last tablet of study treatment (fezolinetant or placebo). After this visit the women will be called twice to check their health. The women will be in the study for about 2 years.
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
oral
PlaceboDrug
oral
TamoxifenDrug
oral
Aromatase inhibitorDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline to Week 4 in the frequency of moderate to severe VMSTime frame: Baseline to Week 4
- Mean change from Baseline to Week 12 in the frequency of moderate to severe VMSTime frame: Baseline to Week 12
- Mean change from Baseline to Week 4 in the severity of moderate to severe VMSTime frame: Baseline to Week 4
- Mean change from Baseline to Week 12 in the severity of moderate to severe VMSTime frame: Baseline to Week 12
Locations
110 sites in 11 countries. Site status is shown where the registry gives one.
Site CA15007
Trois-Rivières, Canada
Site CA15019
Sarnia, Ontario, Canada
Site CA15016
Sault Ste. Marie, Ontario, Canada
Site CA15002
Montreal, Quebec, Canada
Site CA15001
Québec, Quebec, Canada
Site CA15004
Québec, Quebec, Canada
Site CA15003
Sherbrooke, Quebec, Canada
Site CA15020
Victoriaville, Quebec, Canada
Site CZ42006
České Budějovice, Czechia
Site CZ42003
Hořovice, Czechia
Site CZ42002
Hradec Králové, Czechia
Site CZ42011
Nový Jičín, Czechia
Site CZ42001
Olomouc, Czechia
Site CZ42005
Prague, Czechia
Site CZ42008
Prague, Czechia
Site CZ42013
Prague, Czechia
Site CZ42004
Tábor, Czechia
Site CZ42007
Vodňany, Czechia
Site CZ42009
Vsetín, Czechia
Site DK45007
Aalborg, Denmark
Site DE45003
Esbjerg, Denmark
Site DK45009
Hillerød, Denmark
Site DK45002
Næstved, Denmark
Site DE45008
Sønderborg, Denmark
Site FR33003
Angers, France
Site FR33001
Bayonne, France
Site FR33005
Bordeaux, France
Site FR33018
Bordeaux, France
Site FR33017
Caen, France
Site FR33016
Dijon, France
Site FR33013
Le Mans, France
Site FR33007
Lille, France
Site FR33012
Lyon, France
Site FR33008
Montpellier, France
Site FR33002
Saint-Herblain, France
Site DE49001
Bottrop, Germany
Site GR49013
Dresden, Germany
Site DE49009
Leipzig, Germany
Site DE49007
Mönchengladbach, Germany
Site DE49010
München, Germany
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.